Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

Neoadjuvant terapi (Tx) for Merkelcellekarsinom med PD-1-hemmeren Cemiplimab (NeoMatryx)

Neoadjuvant terapi (Tx) for Merkel-cellekarsinom med PD-1-hemmeren Cemiplimab – En randomisert, dobbelblindet, placebokontrollert, ikke-komparativ fase II-studie

The study is a randomized, double blind, placebo-controlled, non-comparative phase II trial that investigates the efficacy of neoadjuvant anti-PD-1 antibody Cemiplimab treatment in patients with clinical stage I or II Merkel cell carcinoma who have have undergone primary tumour excision and are pending sentinel lymph node biopsy.

Studieoversikt

Studietype

Intervensjonell

Registrering (Antatt)

135

Fase

  • Fase 2

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiekontakt

Studer Kontakt Backup

Studiesteder

    • Baden-Wurttemberg
      • Heidelberg, Baden-Wurttemberg, Tyskland, 69120
        • Rekruttering
        • Nationales Centrum für Tumorerkrankungen
        • Ta kontakt med:
          • Jessica Hassel, Prof. Dr.
      • Mannheim, Baden-Wurttemberg, Tyskland, 68161
        • Rekruttering
        • Universitätsklinikum Mannheim
        • Ta kontakt med:
          • Jochen Utikal, Prof. Dr.
      • Tübingen, Baden-Wurttemberg, Tyskland, 72076
        • Rekruttering
        • Universitätsklinikum Tübingen
        • Ta kontakt med:
          • Ulrike Leiter-Stöppke, Prof. Dr.
    • Bavaria
      • Regensburg, Bavaria, Tyskland, 93053
        • Rekruttering
        • Universitätsklinikum Regensburg
        • Ta kontakt med:
          • Sebastian Haferkamp, Prof. Dr.
      • Würzburg, Bavaria, Tyskland, 97080
        • Rekruttering
        • Universitätsklinikum Würzburg
        • Ta kontakt med:
          • Anja Gieserich, Dr.
    • Free and Hanseatic City of Hamburg
      • Hamburg, Free and Hanseatic City of Hamburg, Tyskland, 20246
        • Rekruttering
        • Universitätsklinikum Hamburg-Eppendorf
        • Ta kontakt med:
          • Christoffer Gebhardt, Prof. Dr.
    • Hesse
      • Frankfurt am Main, Hesse, Tyskland, 60590
        • Rekruttering
        • Universitätsklinikum Frankfurt
        • Ta kontakt med:
          • Bastian Schilling, Prof. Dr.
    • North Rhine-Westphalia
      • Bielefeld, North Rhine-Westphalia, Tyskland, 33647
        • Rekruttering
        • Klinikum Bielefeld
        • Ta kontakt med:
          • Selma Ugurel, Prof. Dr.
      • Essen, North Rhine-Westphalia, Tyskland, 45147
        • Rekruttering
        • Universitätsklinikum Essen
        • Ta kontakt med:
          • Dirk Schadendorf, Prof. Dr.
      • Minden, North Rhine-Westphalia, Tyskland, 32429
        • Har ikke rekruttert ennå
        • Johannes Wesling Klinikum Minden
        • Ta kontakt med:
          • Ralf Gutzmer, Prof. Dr.
    • Rhineland-Palatinate
      • Mainz, Rhineland-Palatinate, Tyskland, 55131
        • Rekruttering
        • Universitätsmedizin Mainz
        • Ta kontakt med:
          • Stefan Grabbe, Prof. Dr.
    • Thuringia
      • Erfurt, Thuringia, Tyskland, 99089
        • Rekruttering
        • Helios Klinikum Erfurt
        • Ta kontakt med:
          • Rudolph Herbst, Prof. Dr.

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

18 år og eldre (Voksen, Eldre voksen)

Tar imot friske frivillige

Nei

Kjønn som er kvalifisert for studier

Alle

Beskrivelse

Inclusion criteria

  1. Patient has signed informed written consent.

  2. Patients is 18 years and older at time of signing of written informed consent

  3. Patient has diagnosis of Merkel cell carcinoma in clinical stage II, or in stage I with minimum diameter of 1 cm, with primary tumor already removed and a planned sentinel lymph nodes biopsy still pending.

  4. Patient has ECOG performance status 0-2.

  5. Patients has adequate laboratory parameters particularly for the blood count, renal and liver function parameters.

    1. Absolute number of neutrophils ≥ 1.5 x 109/L
    2. Platelets ≥ 75 x 109/L
    3. Hemoglobin ≥ 9 g/dL
    4. Total bilirubin ≤ 1.5 times the upper limit of normal (ULN) (patients with Gilbert´s Disease and total bilirubin up to 3x ULN may be eligible after approval from trial's medical expert)
    5. AST (SGOT) and ALT (SGPT) ≤ 3x ULN
    6. AP ≤ 2.5x ULN
    7. Serum creatinine ≤ 2x ULN or creatinine clearance ≥ 40 mL/min
  6. Female patients of childbearing potential and male patients with female partners of childbearing potential must agree to remain abstinent (refrain from heterosexual intercourse) or use contraceptive methods that result in a failure rate of <1% per year during the treatment period and for at least 6 months after the last dose of Cemiplimab. Male patients must refrain from donating sperm during this same period. Male patients with a pregnant partner must agree to remain abstinent or to use a condom for the duration of the pregnancy.

  7. Patient must be willing to allow translational work-up of tissue samples (PT, sentinel lymph node biopsy).

Exclusion criteria

  1. Patient has prior sentinel lymph node removal for the current MCC.

  2. Patients received prior treatment with immunotherapy (such as PD-1/PD-L1 or CTL4) or any other systemic anti-tumor (MCC) therapy (incl. investigational therapies)

  3. Patient has active or a history of hematological neoplasms including chronic lymphocytic leukemia (CLL), irrespective if these require treatment or not.

  4. Patient had prior organ transplantation including allogenic stem-cell transplantation.

  5. Patient receives immunosuppressive concomitant medication, EXCEPT for the following:

    i. Intranasal, inhaled, topical steroids, or local steroid injection (e.g., intra-articular injection).

    ii. Systemic corticosteroids at physiologic doses ≤ 10 mg/day of prednisone or equivalent.

    iii. Steroids as premedication for hypersensitivity reactions (e.g., CT scan premedication).

  6. Patient has known hypersensitivity to any component of the Cemiplimab formulation as well as a known history of severe allergic, anaphylactic, or other hypersensitivity reactions to chimeric or humanized antibodies or fusion protein.

  7. Patient has active autoimmune or inflammatory disorders.

  8. Patient has history of interstitial lung disease.

  9. Patient has active infection requiring systemic therapy.

  10. Patient has Active infection requiring systemic therapy, including uncontrolled HIV, HBV and HCV infection or diagnosis of immunodeficiency.

    NOTE: Patients are eligible if:

    • Patients have controlled HIV infection with CD4 counts is > 350 cells/μL and viral load is undetectable [HIV RNA PCR]. Patients with controlled HIV infection must be monitored per local standards during the trial.
    • Patients positive for HBV surface antigen have controlled HBV infection receiving anti-viral therapy and with undetectable serum viral load [HBV DNA PCR]. Patients with controlled infection must undergo periodic monitoring of HBV DNA and p must remain on anti-viral therapy for at least 6 months after last dose of Cemiplimab.
    • Patients positive for HCV antibody have controlled HCV infection with undetectable viral load [HCV RNA PCR].
  11. Patent received vaccination with any live vaccine (e.g., intranasal flu vaccine) within 4 weeks before the first dose of Cemiplimab or planned vaccination with live vaccine during the trial

  12. Female patients, who are pregnant or breast feeding or planning to become pregnant within and 6 months after the end of treatment. Female patients of childbearing potential must have a negative serum β-HCG pregnancy test result within 7 days prior to initiation of study treatment.

  13. Patient has evidence of any other disease, neurologic or metabolic dysfunction, physical examination finding or laboratory finding giving reasonable suspicion of a disease or condition that contraindicates the use of any of the study medications, puts the patient at higher risk for treatment-related complications or may affect the interpretation of study results.

  14. Patient has known substance abuse or other psychological or social conditions that may interfere with the patient's participation in the study or evaluation of the study results

  15. Patient is legally incapacitated or has limited legal capacity

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Primært formål: Behandling
  • Tildeling: Randomisert
  • Intervensjonsmodell: Parallell tildeling
  • Masking: Firemannsrom

Våpen og intervensjoner

Deltakergruppe / Arm
Intervensjon / Behandling
Eksperimentell: Arm A (Cemiplimab)

2 cycles of Cemiplimab (350 mg, i.v., Q3W) followed by sentinel lymph node biopsy

Patients will receive Cemiplimab 350 mg i.v. on day 1 of every 21 days cycle for 2 cycles

Andre navn:
  • LIBTAYO
Placebo komparator: Arm B (placebo)

2 cycles of placebo followed by sentinel lymph node biopsy

Patients will receive NaCl 0.9% solution i.v. on day 1 of every 21 days cycle for 2 cycles.

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Nodal micrometastases-free rate
Tidsramme: up to 36 months

rate of patients without nodal micrometastases after 2 cycles of treatment, determined by sentinel lymph node biopsy

up to 36 months

Sekundære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Recurrence-free survival
Tidsramme: up to 66 months

time from randomization until date of the first of the following events: MCC recurrence, and MCC-related death

up to 66 months
Time to recurrence
Tidsramme: up to 66 months

defined as time from randomization until date of first MCC recurrence

up to 66 months
Overall survival
Tidsramme: up to 66 months

time from randomization until date of death from any cause

up to 66 months
Quality of life using FCRI-SF questionnaire
Tidsramme: up to 66 months

Quality of life determined using the FCRI-SF questionnaire

up to 66 months
Safety (AEs and SAEs)
Tidsramme: up to 66 months

incidence, nature, causality, frequency, timing and severity of adverse events using NCI CTCAE 5

up to 66 months
Disease specific survival
Tidsramme: up to 66 months

time from randomization until date of MCC-related death

up to 66 months
Quality of life using the mFACT-M questionnaire
Tidsramme: up to 66 months

Quality of life determined using the mFACT-M questionnaire

up to 66 months

Andre resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Investigation of prognostic and predictive biomarkers to estimate the risk of lymph node metastases and signs of immune activation in the sentinel lymph nodes
Tidsramme: up to 66 months

Biosamples will be used to determine the correlation of identified biomarkers with clinical outcome, i.e., nodal metastases-free rate, RFS, OS

up to 66 months

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Etterforskere

  • Studieleder: Salah Al-Batran, Prof. Dr., Institut für Klinische Krebsforschung IKF GmbH
  • Hovedetterforsker: Ralf Gutzmer, Prof. Dr. med., Johannes Wesling Klinikum Minden
  • Hovedetterforsker: Juergen C. Becker, Prof. Dr. Dr., Translational Skin Cancer Research University Duisburg-Essen, Germany

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Faktiske)

29. mai 2026

Primær fullføring (Antatt)

31. desember 2029

Studiet fullført (Antatt)

31. juli 2031

Datoer for studieregistrering

Først innsendt

28. januar 2026

Først innsendt som oppfylte QC-kriteriene

28. januar 2026

Først lagt ut (Faktiske)

4. februar 2026

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

9. november 2026

Siste oppdatering sendt inn som oppfylte QC-kriteriene

4. november 2026

Sist bekreftet

1. november 2026

Mer informasjon

Begreper knyttet til denne studien

Plan for individuelle deltakerdata (IPD)

Planlegger du å dele individuelle deltakerdata (IPD)?

NEI

Legemiddel- og utstyrsinformasjon, studiedokumenter

Studerer et amerikansk FDA-regulert medikamentprodukt

Nei

Studerer et amerikansk FDA-regulert enhetsprodukt

Nei

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .

Abonnere